Original Scientific Article
Retrospective study on trilostane titration dose treatment in dogs with terminal stage of hyperadrenocorticism
Irena Celeska * ,
Martin Nikolovski ,
Todor Novakov ,
Anastasija Angelovska ,
Ivica Gjurovski ,
Elena Atanaskova Petrov

Mac Vet Rev 2024; 47 (1): 51 - 57


Received: 16 January 2024

Received in revised form: 12 February 2024

Accepted: 20 February 2024

Available Online First: 28 February 2024

Published on: 15 March 2024

Correspondence: Irena Celeska, iceleska@fvm.ukim.edu.mk


Hyperadrenocorticism (HAC) in dogs is routinely treated with trilostane single-dose (CTG) which is reported to cause adverse reactions. The current retrospective study of several dogs with terminal stage of HAC aimed to compare the clinical, hematological, and biochemical effects of trilostane titration-dose treatment (TTG) with the single-dose treatment (CTG). All clinical cases (n=7) were confirmed on HAC by anamnestic, clinical, hematology, biochemistry, and low-dose dexamethasone suppression test findings, indicative for Cushing’s disease. Two cases were treated with CTG (2.2-6.7 mg/kg, single dose daily) and their treatment was discontinued on the second week due to adverse reactions. The TTG cases were treated for up to 12 weeks (0.5 mg/kg once daily for 7 days, and then with 0.5 mg/kg twice daily for 7 days). Blood samples and clinical checks were performed on 0., 4., and 12. weeks of the treatment. Hemoglobin was non-significantly higher in TTG at 12 weeks. Alanine transaminase was significantly lower in the TTG cases on the 12. week of the treatment (78.04±15.37 U/L) compared to the 0-week (137.81±24.03 U/L), and 4-week samples (131.92±23.36 U/L). No significant differences were observed with the CTG cases. Alkaline phosphatase was significantly lower on 12-week samples in TTG (251.02±93.06) compared to the 4-week (567.94±283.93 U/L), and 0-week samples (1,341.84 U/L). In conclusion, TTG has indicated to have significantly higher tendency to decrease alanine transaminase and alkaline phosphatase, alleviating the negative effects on the liver. The clinical findings were more adverse for the CTG.

Keywords: Cushing’s disease, dogs, trilostane


1. Feldman, E.C., Nelson, R.W. (2004). Canine hyperadrenocorticism Cushings syndrome. In: Canine and Feline Endocrinology and Reproduction (p. 252). Elsevier Health Sciences.
2. Kritsepi-Konstantinou, M., Oikonomidis, I.L. (2016). The interpretation of leukogram in dog and cat. HJCAM 5(2): 63.
3. Ryad, N.M., Ramadan, E.S., Salem, N.Y., Saleh, I.A. (2021). Influence of dexamethasone administration on hematology, biochemistry, and thyroid hormones in dogs. Adv Anim Vet Sci. 9(1): 111-116. https://doi.org/10.17582/journal.aavs/2021/ 
4. Peterson, M.E. (2007). Diagnosis of hyperadrenocorticism in dogs. Clin Tech Small Anim Pract. 22(1): 2-11. https://doi.org/10.1053/j.ctsap.2007.02.007 PMid:17542191
5. Behrend, E.N., Kooistra, H.S., Nelson, R., Reusch, C.E., Scott‐Moncrieff, J.C. (2013). Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal). J Vet Intern Med. 27(6): 1292-1304. https://doi.org/10.1111/jvim.12192 PMid:24112317
6. Potts, G.O., Creange, J.E., Harding, H.R., Schane, H.P. (1978). Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 32(2): 257-267. https://doi.org/10.1016/0039-128X(78)90010-7 PMid:715820
7. Eastwood, J.M., Elwood, C.M., Hurley, K.J. (2003). Trilostane treatment of a dog with functional adrenocortical neoplasia. J Small Anim Pract. 44(3): 126-131. https://doi.org/10.1111/j.1748-5827.2003.tb00133.x PMid:12653328
8. Neiger, R., Hurley, K.J., Ramsey, I., O’Connor, J., Mooney, C.T. (2002). Trilostane treatment of 78 dogs with pituitary‐dependent hyperadrenocorticism. Vet Rec. 150(26): 799-804. https://doi.org/10.1136/vr.150.26.799 PMid:12120922
9. Lemetayer, J., Blois, S. (2018). Update on the use of trilostane in dogs. Can Vet J. 59(4): 397-407.
10. Bell, R., Neiger, R., McGrotty, Y., Ramsey, I.K. (2006). Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs. Vet Rec. 159(9): 277-281. https://doi.org/10.1136/vr.159.9.277 PMid:16946310
11. Vaughan, M.A., Feldman, E.C., Hoar, B.R., Nelson, R.W. (2008). Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc. 232(9): 1321-1328. https://doi.org/10.2460/javma.232.9.1321 PMid:18447776
12. Feldman, E.C. (2011). Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc. 238(11): 1441-1451. https://doi.org/10.2460/javma.238.11.1441 PMid:21627507
13. Teshima, T., Hara, Y., Takekoshi, S., Nezu, Y., Harada, Y., Yogo, T., Teramoto, A., Osaamura, R.Y., Tagawa, M. (2009). Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis. Domest Anim Endocrinol. 36(1): 32-44. https://doi.org/10.1016/j.domaniend.2008.10.002 PMid:19041802
14. Gilor, C., Graves, T.K. (2011). Interpretation of laboratory tests for canine Cushing’s syndrome. Top Companion Anim Med. 26(2): 98-108. https://doi.org/10.1053/j.tcam.2011.03.001 PMid:21596349
15. Fathman, L. (2005). Textbook of veterinary internal medicine. Elsevier Saunders
16. Jacoby, R.C., Owings, J.T., Ortega, T., Gosselin, R., Feldman, E.C. (2001). Biochemical basis for the hypercoagulable state seen in Cushing syndrome; discussion 1006-7. Arch Surg. 136(9): 1003-1006. https://doi.org/10.1001/archsurg.136.9.1003 PMid:11529821
17. Galac, S. (2010). Recent developments in canine Cushings syndrome. Utrecht University
18. Cho, K.D., Kang, J.H., Chang, D., Na, K.J., Yang, M.P. (2013). Efficacy of low‐ and high‐dose trilostane treatment in dogs (<5 kg) with pituitary‐dependent hyperadrenocorticism. J Vet Intern Med. 27(1): 91-98. https://doi.org/10.1111/jvim.12007 PMid:23167780
19. Ettinger, S.J., Feldman, E.C. (2010). Textbook of veterinary internal medicine. 7th edition, 2086-2088.
20. Alenza, D.P., Arenas, C., Lopez, M.L., Melian, C. (2006). Long-term efficacy of trilostane administered twice daily in dogs with pituitarydependent hyperadrenocorticism. J Am Anim Hosp Assoc. 42(4): 269-276. https://doi.org/10.5326/0420269 PMid:16822765


© 2024 Celeska I. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conflict of Interest Statement

The authors declared that they have no potential lict of interest with respect to the authorship and/or publication of this article.

Citation Information

Macedonian Veterinary Review. Volume 47, Issue 1, Pages 51-57, e-ISSN 1857-7415, p-ISSN 1409-7621, DOI: 10.2478/macvetrev-2024-0016